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Background: Publication bias is a major threat to the validity of systematic reviews. Searches of clinical trials
registries can help to identify unpublished trials, though little is known about how often these resources are
utilized. We assessed the usage and results of registry searches reported in systematic reviews published in major
general medical journals.
Methods: This cross-sectional analysis includes data from systematic reviews assessing medical interventions which
were published in one of six major general medical journals between July 2012 and June 2013. Two authors
independently examined each published systematic review and all available supplementary materials to determine
whether at least one clinical trials registry was searched.
Results: Of the 117 included systematic reviews, 41 (35%) reported searching a trials registry. Of the 29 reviews
which also provided detailed registry search results, 15 (52%) identified at least one completed trial and 18 (62%)
identified at least one ongoing trial.
Conclusions: Clinical trials registry searches are not routinely included in systematic reviews published in major
medical journals. Routine examination of registry databases may allow a more accurate characterization of
publication and outcome reporting biases and improve the validity of estimated effects of medical treatments.
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Systematic reviews are an important means of synthesizing
medical research findings to inform medical decision making.
The validity of conclusions from systematic reviews depends
on the authors’ abilities to identify all previously conducted
research relevant to the subject and of sufficient quality to be
informative. Because non-publication of original research
results that are negative or undesirable threatens the validity
of conclusions from systematic reviews, methods have been
developed to assess the identified literature for publication
bias. These methods, which include the inspection and
testing of funnel plots, are now routinely performed and
explicitly mentioned in the guidelines for the reporting of
systematic reviews [1-3]. However, these methods are* Correspondence: Cjones.unc@gmail.com
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unless otherwise stated.imperfect. At best they suggest the presence of unpublished
small- or moderately-sized studies based on the assumption
that the largest studies on the subject are published, an
assumption which may often be incorrect [4]. Empirical
analyses indicate that these methods do not reliably detect
publication bias [5,6].
Clinical trials registries allow researchers, clinicians, and
the general public to learn about clinical trials conducted on
a subject regardless of whether the results have been
published. Since 2005, the International Committee of
Medical Journal Editors (ICMJE) has required that pros-
pective trials involving human participants undergo registra-
tion prior to initiating study enrollment as a condition of
publication in member journals [7]. Following the passage
of the United States Food and Drug Administration
Amendments Act (FDAAA) in 2007, prospective trial regis-
tration became a requirement under United States law for
many interventional clinical trials [8]. Thus, clinical trialstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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recently initiated clinical trials. Policies supporting trial
registration have been motivated in large part by the belief
that consistent pre-registration of clinical trials will help
consumers of the medical literature monitor and account
for publication bias and other forms of selective reporting
[7,9,10].
Awareness of clinical trial results which remain unpub-
lished and unavailable can have important consequences
for the conclusions drawn from systematic reviews [11].
Commonly referenced guidelines for the conduct of
systematic reviews recommend a search of trials registries
as part of a comprehensive search strategy [12,13]. How-
ever, whether authors of systematic reviews typically
comply with these guidelines is unclear. Our objective was
to determine what proportion of authors of systematic
reviews recently published in high-impact general medical
journals searched clinical trials registries in order to
identify relevant unpublished studies.Methods
Data sources
We identified systematic reviews published between July
1, 2012 and June 30, 2013 in six high-impact general
medical journals: Annals of Internal Medicine, BMJ, The
Journal of the American Medical Association (JAMA),
The Lancet, The New England Journal of Medicine, and
PLoS Medicine. These journals were chosen because the
manuscripts contained therein have a substantial influence
on clinical practice and because they also set precedent for
medical research methodology. Systematic reviews were
identified by searching MEDLINE via PubMed using the
following search terms: (Meta-analysis[Publication Type]
OR meta-analysis[Title/Abstract] OR meta-analysis[MeSH
Terms] OR review[Publication Type] OR search*[Title/
Abstract]). This search strategy has been shown to be
sensitive for the identification of published systematic
reviews [14]. We used the advanced search feature of
PubMed to restrict the search to manuscripts with publi-
cation dates between July 1, 2012 and June 30, 2013 in the
six aforementioned journals.
One study author (CWJ) reviewed the full manuscripts
identified during this initial search to determine whether
or not each publication included a systematic review. We
classified articles as systematic reviews based on pre-
viously developed criteria: the manuscript included a clear
statement identifying the topic of the review; authors
provided a detailed description of the methods and data-
sources used to identify evidence included in the review;
the manuscript included explicit inclusion and exclusion
criteria; and the results included at least one study which
met these inclusion criteria [14]. Two study authors (CWJ
and LGK) evaluated the included systematic reviews todetermine whether the primary goal of each was to assess
the effects of an intervention.Outcome measures
For each systematic review, two authors (CWJ and LGK)
independently reviewed the full text, including appendices
and online supplements. The primary outcome was
whether the systematic review included a search of at least
one clinical trials registry. ClinicalTrials.gov and those
trials registries meeting World Health Organization
(WHO) Primary Registry Criteria, version 2.1, were in-
cluded [15] The WHO criteria require that registries pledge
to make prospectively registered trial information freely
available to the general public. Additional requirements
include the ability to track and record any changes made to
registry entries, implementation of quality control proce-
dures to ensure the accuracy and completeness of registry
data, and management by a not-for-profit agency. Fourteen
registries met these requirements at the time of our
analysis, including the International Standard Randomised
Controlled Trial Number Register and the European Union
Clinical Trials Register [15]. Discrepancies between authors
with respect to trial registry utilization among the included
systematic reviews were resolved by consensus.Study variables
When authors indicated that a trials registry search was part
of their review protocol, we reviewed the manuscript and all
available supplementary materials to determine the number
of relevant ongoing or completed studies which were identi-
fied as a result of the registry search. For the reviews in
which this information was ambiguous or unavailable we
emailed the corresponding author to request additional
details regarding their search results. We also reviewed full
manuscripts and all available supplementary materials to
determine whether review authors provided search terms
which would allow for the replication of the registry search.
We searched each manuscript for a statement from study
authors indicating whether the review was compliant with
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) reporting guidelines for system-
atic reviews. Additionally, we gathered information about
study funding and author financial disclosures for each
manuscript. Both author support and direct study funding
were considered together when categorizing reviews by
funding source.
Because clinical trials are more commonly registered
than observational studies, registry data are likely to be
most relevant to those systematic reviews which evaluate
interventions. For this reason, our analysis was limited to
those systematic reviews which had a stated primary goal
of assessing an intervention in a human population.
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Inter-rater agreement for our primary outcome was calcu-
lated using Cohen’s kappa. Statistical analyses were per-
formed using SPSS version 20.0 (IBM, Armonk, New York).
Results
Our PubMed search retrieved 567 records published
between July 1, 2012 and June 30, 2013, 177 of which were
determined to be systematic reviews (Additional file 1). Of
these, 117 (66%) had a stated primary objective of asses-
sing the effects of an intervention and therefore compose
our primary study sample. A search of one or more
clinical trials registries was described as part of the litera-
ture search protocol in 41 (35%) of these 117 manuscripts
(Table 1). Subgroup analysis by journal and by funding
source showed that there was no subgroup in this sample
for which searches of clinical trial registries occurred in
more than 50% of the systematic reviews. For 37 reviews,
authors reported searching ClinicalTrials.gov either dir-
ectly or through a registry search portal (International
Clinical Trials Registry Platform (ICTRP) or Current
Controlled Trials). Nineteen of these 37 reviews included
searches of other registries in addition to ClinicalTrials.
gov. Four reviews did not specify which trials registries
were searched. For the remaining 76 reviews (65%),
authors did not report searching a registry.
Detailed registry search results were available for 29
reviews. Authors reported finding at least one relevant
completed study as a result of their registry search for 15
of these 29 reviews (52%) and at least one ongoing study
for 18 of these reviews (62%; Figure 1). Twenty-three ofTable 1 Characteristics of systematic reviews published in six
Review characteristics All interv
(n =117)
Journal, n (%)
Annals of Internal Medicine 41
BMJ 37
The Journal of the American Medical Association 11
The Lancet 12
The New England Journal of Medicine 1
PLOS Medicine 15
Funding source, n (%)a
Industry 38
NIHb/government 81
Other 32
None 13
Manuscript reported PRISMA compliance 38
Number of individual studies included in review, median (range) 30 (5–639)
aReviews with multiple funding sources are listed within all relevant categories; tota
bNational Institutes of Health.the 29 reviews (79%) found at least one completed or
ongoing study during the registry search. The authors of
one of these 23 reviews indicated that they had identified
both relevant completed and ongoing studies as a result of
their registry search, but they were unable to provide the
specific number of studies in each category [16]. Among
the reviews for which specific data were available, the
median number of relevant studies identified through
registry searches was 2 (range 0–49). For six reviews,
authors reported finding no relevant ongoing or com-
pleted studies as a result of their registry searches. Seven
manuscripts provided the specific terms used to perform
the registry search.
Cohen’s kappa coefficient for inter-rater reliability with
respect to whether systematic reviews included registry
searches was 0.98, indicating excellent agreement.
Discussion
Clinical trials registries were not routinely included as part
of the search strategies utilized for this group of systematic
reviews published in high-impact general medical journals.
Our results show that just 35% of these systematic reviews
reportedly incorporated searches from any clinical trials
registry. When review authors did search trials registries,
however, completed but unpublished studies were identi-
fied in approximately half of cases and ongoing studies
identified in the majority of cases. These findings suggest
that trials registries are an underutilized resource among
investigators conducting systematic reviews.
Prior investigations have demonstrated that a substan-
tial proportion of clinical trials are completed but nevermajor medical journals from July 2012 through June 2013
entional reviews Searched a registry
(n =41)
No registry search described
(n =76)
16 (39) 25 (61)
13 (35) 24 (65)
4 (36) 7 (64)
4 (33) 8 (67)
0 (0) 1 (100)
4 (27) 11 (73)
17 (45) 21 (55)
29 (36) 52 (64)
11 (34) 21 (66)
4 (31) 9 (69)
18 (47) 20 (53)
35 (5–639) 29 (5–379)
ls therefore add to more than 100%.
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Figure 1 Registry search results by systematic review [17-44]. N =28; one review reported finding “several” relevant ongoing trials.
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gov, approximately one in three remain unpublished [46,47],
and the rate of non-publication is almost as high for large
trials [4]. These estimated rates of non-publication are par-
ticularly important given the increasing numbers of trials be-
ing registered and conducted. In January of 2005, 12,000
studies had been registered at ClinicalTrials.gov; by October
2013 over 152,000 studies had been registered [48]. Other
registries have reported similar growth rates [49]. Thus,
clinical trials registries potentially contain a large amount of
trial information which is not available in the published
literature.
In an effort to make ClinicalTrials.gov more effective at
combating publication bias, the United States FDAAA of
2007 expanded the scope of ClinicalTrials.gov via the
creation of a results database. The FDAAA mandated that
results from nearly all phase II-IV human-subjects trials of
FDA-approved drugs or devices conducted within the
United States be submitted to ClinicalTrials.gov within one
year of the study completion date, regardless of publication
status [50]. As utilization of the results database improves,
ClinicalTrials.gov will contain outcome data from an in-
creasing number of otherwise unpublished studies. The
availability of results will allow a trials registry search to not
only inform investigators about the potential for publication
bias but also allow for correction of this bias.
Even among registered studies without results available
on ClinicalTrials.gov, registry entries are likely to containinformation of significant value to the authors of system-
atic reviews. First, comparing registered studies to pub-
lished studies allows identification of unpublished trials,
and authors of systematic reviews can use the number and
sample sizes of unpublished studies in combination with
other methods such as funnel plots to better describe the
possible impact of publication bias on effect estimates. For
example, particular caution should be exercised when
drawing conclusions from pooled data when registry
searches reveal the existence of unpublished trials with
large sample sizes relative to the subset of published trials.
Second, even when trial results are published, examining
registry entries can help review authors identify outcome
reporting bias by allowing them to compare a priori
planned outcomes to reported outcomes [51,52]. Add-
itionally, registry entries frequently include contact infor-
mation for study investigators, thereby providing review
authors with the opportunity to contact investigators to
request information about unpublished or incompletely
reported studies. A recent comparison between published
trial results and results posted on ClinicalTrials.gov also
showed that ClinicalTrials.gov was far more likely than a
published manuscript to include a complete accounting of
adverse study events [53]. Finally, registry searches may
reveal the existence of ongoing or recently completed
trials, allowing the authors of systematic reviews to more
accurately discuss their results within the context of
ongoing research.
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Cochrane systematic reviews published between 2008 and
2010, in which trials registry searches were only included in
38% of reviews [54]. This study found that for the reviews
in which registry search results were reported, relevant
completed or ongoing trials were identified just 45% of the
time. In our study, at least one relevant completed or
ongoing trial was identified by 79% of the reviews reporting
registry search results. One possible explanation for this
difference is that the utility of registry searches may be
increasing with time as trial pre-registration becomes more
commonplace.
Since 2009 the Centre for Reviews and Dissemination
has identified ClinicalTrials.gov and other public trials
registries as important resources for identifying trial re-
sults [55]. Other commonly referenced guidelines for the
conduct of systematic reviews, including those produced
by the Institute of Medicine and the Agency for Health-
care Research & Quality, have strongly recommended the
use of a clinical trials registry search as part of a compre-
hensive search strategy since 2011 [12,13]. Further, the
Cochrane Handbook recommends that Cochrane Review
authors search registries in order to assess both for com-
pleted but unpublished and for ongoing trials [56]. Despite
these recommendations, our results show that trials regis-
tries are not routinely utilized by systematic review
authors. The PRISMA Statement, which has been
endorsed by the World Association of Medical Editors,
the Cochrane Collaboration, and numerous other organi-
zations and journals, and provides a guide to the reporting
of systematic reviews, does not explicitly advise authors to
search trial registries [1]. While PRISMA is intended to be
a guide to systematic review reporting, it is probably also
used by investigators as a guide to systematic review con-
duct. As compliance with trial registration requirements
and use of the ClinicalTrials.gov database for reporting re-
sults increase, revisions to PRISMA that place greater em-
phasis on incorporating registry data into systematic
reviews may be useful in raising awareness among authors
of systematic reviews of the potential importance of this
resource.
Several limitations should be considered when inter-
preting these results. Not all systematic reviews address
topics which can be studied with a clinical trial, and it is
possible that even among the group of reviews which
assessed interventions, some review authors decided not
to search a trial registry because they thought that there
were no relevant trials on the subject. However, registry
data may be valuable even for authors conducting system-
atic reviews of subjects not amenable to clinical trials.
Currently over 27,000 observational studies are registered
with ClinicalTrials.gov, accounting for 18% of the data-
base’s registry entries, and the authors of observational
studies are increasingly being encouraged to prospectivelyregister their studies [48,57]. ClinicalTrials.gov functions
as a significant source of registry data from non-
interventional studies, and even systematic reviews that
examine questions not easily tested with a clinical trial
may benefit from registry searches. Additionally, we did
not assess the impact of searching industry-sponsored re-
sults databases in this analysis, though these databases can
also be important sources of unpublished trial data [58].
The external validity of our results may also be limited.
We studied systematic reviews published in a group of
high-impact general medicine journals; it is possible that
different patterns would be observed among other journals.
Also, it is probable that some systematic reviews meeting
our inclusion criteria were missed by our search strategy.
However, the strategy we employed has previously been
validated as a sensitive method of identifying systematic
reviews, and it is unlikely that any systematic reviews we
overlooked would have a substantively different rate of
searching trials registries.
Conclusions
In this sample of recently published systematic reviews in
major medical journals, searches of clinical trials registries
were not routinely utilized. In the cases where registry
searches were performed, authors identified relevant com-
pleted or ongoing trials more than three quarters of the
time. More consistent use of trials registry databases may
improve the identification of publication and outcome
reporting biases and increase the validity of estimated
effects of medical treatments in systematic reviews.
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